Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

Vaccine

Volumn 14, Issue 10, 1996, Pages 1009-1015

  Peeters, C C A M ^a   Rumke H C ^a   Sundermann, L C ^a   Rouppe Van Der Voort, E M ^a   Meulenbelt, J ^a   Schuller, M ^a   Kuipers, A J ^a   Van Der Ley, P ^a   Poolman, J T ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Meningococcal vaccine; Outer membrane vesicle; PorA

Indexed keywords

ALUMINUM PHOSPHATE; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY; OUTER MEMBRANE PROTEIN; PLACEBO; PORIN; RECOMBINANT VACCINE; THIOMERSAL;

ADULT; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL PROTOCOL; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; GASTROENTERITIS; GENETIC ENGINEERING; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MALAISE; MEMBRANE VESICLE; MENINGOCOCCOSIS; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION; VOLUNTEER;

EID: 0030197579     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(96)00001-1     Document Type: Article

References (17)

1. 1 Poolman, J.T., Timmermans, J.A.M., Hopman, C.T.P., Teerlink, T., Van Vught, P.A.M. and Beuvery, E.C. Comparison of meningococcal outer membrane protein vaccines, solubilized with detergent or C polysaccharide. Antonie van Leeuwenhoek 1987, 53, 413-419
2. 2 Poolman, J.T., Van der Ley, P.A., Wiertz, E.J.H.J. and Hoogerhout, P. Second generation meningococcal OMP-LPS vaccines. NIPH Ann. 1991, 14, 233-241
3. 3 Poolman, J.T. Development of a meningococcal vaccina. Infect. Agents Dis. 1995, 4, 13-28
4. 4 Saukkonen, K., Leinonen, M., Abdillahi, H. and Poolman, J.T. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 1989, 7, 325-328
5. 5 Van der Ley, P.A. and Poolman, J.T. Construction of a multivalent class 1 OMP expressing meningococcal vaccine strain. Infect. Immun. 1992, 60, 3156-3161
6. 6 Van der Ley, P.A., Heckels, J.E., Virji, M., Hoogerhout, P. and Poolman, J.T. Topology of outer membrane porins in pathogenic Neisseria spp. Infect. Immun. 1991, 59, 2963-2971
7. 7 Bjune, G., Høiby, E.A., Grønnesby, J.K. et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991, 338, 1093-1096
8. 8 The Chilean National Committee for Meningocococal Disease, Zollinger, W.D., Boslego, J., Moran, E. et al. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. NIPH Ann. 1991, 14, 211-213
9. 9 Cassio de Moraes, J., Perkins, B.A., Camargo, M.C.C. et al. Protective efficacy of a serogroup B meningococcal vaccine in Sāo Paulo Brazil. Lancet 1992, 340, 1074-1078
10. 10 Milagres, L.G., Ramos, S.R., Sacchi, C.T. et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 1994, 62, 4419-4424
11. 11 Høiby, E.A., Rosenqvist, E.A., Frøholm, L.O. et al. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann. 1991, 14, 147-156
12. 12 Van der Ley, P.A., Van der Biezen, J. and Poolman, J.T. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of multivalent outer membrane vesicle vaccine. Vaccine 1995, 13, 401-407
13. 13 Claassen, I., Meylis, J., Van der Ley, P. et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine, this issue
14. 14 Frasch, C.E., Zollinger, W.D, and Poolman, J.T. Serotype antigenes of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev. Infect. Dis. 1985, 7, 504-510
15. 15 Abdillahi, H. and Poolman, J.T. Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA. Microb. Pathog. 1988, 4, 27-32
16. 16 Tommassen, J., Vermey, P., Struyvé, M., Benz, R. and Poolman, J.T. Isolation of mutants of Neisseria meningitidis deficient in class 1 (por A) and class 3 (por B). Infect. Immun. 1990, 58, 1355-1359
17. 17 Frederiksen, J.H., Rosenqvist, E., Wedege, E. et al. Production, characterization and control of MenB-vaccine ≪Folkehelsa: an outer membrane vesicle vaccine against group B meningo-coccal disease. NIPH Ann. 1991, 14, 67-80